Sign In
Buy NXTC
$3.15
-0.250 (-7.35%)
At Close: Jun 03, 2026
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
08:05am, Tuesday, 05'th Mar 2024
BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
11:16am, Monday, 25'th Dec 2023
NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mea
BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
12:46pm, Friday, 15'th Dec 2023
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
NextCure Provides Year-End Clinical Pipeline Updates
06:45am, Thursday, 14'th Dec 2023
BELTSVILLE, Md., Dec. 14, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
07:00am, Monday, 20'th Nov 2023
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
04:05pm, Wednesday, 15'th Nov 2023
BELTSVILLE, Md., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
01:32pm, Tuesday, 07'th Nov 2023
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
04:05pm, Thursday, 02'nd Nov 2023
BELTSVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease
04:05pm, Tuesday, 26'th Sep 2023
BELTSVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedic
• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Thursday, 31'st Aug 2023
BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NextCure to Present at the JMP Securities Life Sciences Conference
07:00am, Tuesday, 09'th May 2023
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine
